1. Urinary peptide profiling identifies a panel of putative biomarkers for diagnosing and staging endometriosis 
Muna M. El-Kasti, Ph.D., Cynthia Wright, Ph.D., Haddy K.S. Fye, B.Sc., Fenella Roseman, M.Sc., Benedikt M. Kessler, Ph.D., Christian M. Becker, M.D. 
Fertility and Sterility 
Volume 95, Issue 4, Pages e6 (March 2011)
DOI: /j.fertnstert
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
MALDI-TOF-MS analysis of urinary peptide profiles from controls and endometriosis patients. (A) Representative peptide mass spectra of controls (red) and endometriosis patients (green) during the periovulatory phase. (B) Representative peptide mass spectra from the three menstrual phases of a control and a moderate/severe endometriosis patient. The x-axis is the mass/charge ratio (m/z) and the y-axis is the peak intensity in arbitrary units (a.u.).
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

3. Figure 2
Statistical analysis of MALDI-TOF-MS urinary peptide profiles comparing controls with moderate/severe endometriosis patients. Receiver operating characteristic (ROC) plot of the statistically significant putative diagnostic urinary peptide markers from (A) the periovulatory phase (1,767.1 Da) and (B) the luteal phase (1,824.3 Da).
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

4. Figure 3
Statistical analysis of MALDI-TOF-MS urinary peptide profiles comparing minimal/mild to moderate/severe endometriosis patients. Receiver operating characteristic (ROC) plot of the statistically significant putative diagnostic urinary peptide markers from (A) the periovulatory phase (3,280.9 Da) and (B) the luteal phase (1,933.8 Da).
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

5. Urinary peptides of intensity of peaks x (m/z) and y (m/z) detected by MALDI-TOF-MS when plotted against each other, distinguished between controls (red) and moderate/severe (green) endometriosis patients during (A) the periovulatory phase and (B) the luteal phase.
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

6. Statistical analysis of MALDI-TOF-MS urinary peptide profiles comparing controls with moderate/severe endometriosis patients. Scatter plot for (A) the periovulatory mass peak (1,767.1 Da) and (B) the luteal mass peak (1,824.3 Da) showing the cutoff point (CP: maroon horizontal line) for the best sensitivity (S) and specificity (Sp) combination. Periovulatory phase (CP ≥35.2): S = 75%; Sp = 85%. Luteal phase (CP ≥29.3): S = 75%; Sp = 71%.
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

7. Urinary peptides of intensity of peaks x (m/z) and y (m/z) detected by MALDI-TOF-MS when plotted against each other, distinguished between minimal/mild (red) and moderate/severe (green) endometriosis patients during (A) the periovulatory phase and (B) the luteal phase.
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

8. Statistical analysis of MALDI-TOF-MS urinary peptide profiles comparing minimal/mild with moderate/severe endometriosis patients. Scatter plot for (A) the periovulatory mass peak (3,280.9 Da) and (B) the luteal mass peak (1,933.8 Da) showing the cutoff point (CP: maroon horizontal line) for the best sensitivity (S) and specificity (Sp) combination. Periovulatory phase (CP ≥31.3): S = 82%; Sp = 88%. Luteal phase (CP ≥54.1): S = 75%; Sp = 75%.
Fertility and Sterility  , e6DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions